



# Signalife

Clear Data. Trusted Results.

Signalife, Inc.  
531 South Main St. ~ Suite 301  
Greenville, SC 29601  
T 864.233.2300  
F 864.233.2100  
www.signalife.com  
info@signalife.com

## PRESS RELEASE

Wednesday August 11, 2004 | 9:10 AM ET

### **Duke University to Evaluate Recom Managed Systems' Model 100 12-Lead Ambulatory Heart Monitoring System**

LOS ANGELES—(BUSINESS WIRE)—August 11, 2004 Recom Managed Systems, Inc. (OTCBB:RECM – News) and Duke Clinical Research Institute (“Duke”) announced entering into a letter of intent to evaluate the performance of the Recom Model 100 ambulatory ECG monitoring system (“Study”). This market preference testing will establish the Model 100’s performance against currently marketed ECG monitoring devices.

Pursuant to the terms of the letter of intent, Recom will provide funding for the initial commitment of time and resources by Duke in connection with the development of Study protocols and Institutional Review Board (“IRB”) approval for such Study. In the event a definitive agreement is not reached between the parties by August 30, 2004, the letter of intent shall terminate. No human subject(s) research activities will begin until the definitive agreement is executed. Notwithstanding the forgoing, there can be no assurance that a definitive agreement will be reached. Duke will have no commercial participation in the product or its sale.

With regard to the anticipated Study, Duke’s responsibilities may include: (i) strategy development, (ii) protocol development, (iii) study planning, (iv) interim analysis, (v) a Clintrial database and (vi) final study report. Commenting on the Study, Marvin H. Fink, Recom’s CEO stated: “We are excited about the opportunity to work with such a prestigious organization as Duke. I feel confident that this Study will generate the clinical findings that demonstrate the advantages of Recom’s ambulatory monitoring system.”

The Recom ECG monitor system utilizes the company’s patented signal technology that produces a high-fidelity ECG signal in the presence of ambient noise. This research is intended to demonstrate that a Recom 12-lead ambulatory recording can produce ECG data on a par with other 12-lead modalities such as resting ECG and exercise stress testing.

### **About Recom Managed Systems, Inc.**

Recom Managed Systems, Inc. is an emerging life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal technology platform, Recom brings clinical quality physiological signal monitoring to the ambulatory setting.

### **Caution Regarding Forward-Looking Statements**

Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Recom’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom’s products or services, adverse equity market conditions and declines in the value of Recom’s common stock, and the unavailability of financing to complete management’s plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom’s filings with the Securities and Exchange Commission.

Contact:  
Rodney Hildebrandt  
COO  
Recom Managed Systems  
(864) 233-2300

Source: Recom Managed Systems

